Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ALV003

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
This is a selective review of the literature concerning the methods of celiac disease treatment, which can be an alternative to a… Expand
Review
2015
Review
2015
  • H. Freeman
  • Expert opinion on emerging drugs
  • 2015
  • Corpus ID: 24373780
Introduction: Celiac disease is an immune-mediated gluten-dependent disorder, primarily affecting the small intestine in… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease, necessitating strict… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2014
2014
  • S. Crowe
  • Gastroenterology
  • 2014
  • Corpus ID: 34905352
EDITORIALS Management of Celiac Disease: Beyond the Gluten-Free Diet See “Glutenase ALV003 attenuates gluten-induced mucosal… Expand
2013
2013
teamed up to develop ALV003, which is a novel oral treatment that is currently in Phase II development for patients with celiac… Expand
Highly Cited
2011
Highly Cited
2011
BackgroundCeliac disease is the most common hereditary autoimmune disease in humans. The only treatment option for non-refractory… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2010
Highly Cited
2010
Effective treatment of celiac disease is an unmet medical need. A glutenase that destroys immunogenic gluten peptides may be… Expand